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Review Article
Abstract
Photon dose calculation algorithms in treatment planning system could affect the accuracy of dose delivery when tissue heter-
ogeneity is involved along the beam path. Treatment planning for lung cancer is challenging, especially in the case of treatment
plan involving small fields. The combination of low-density (air) medium and small fields cause charge particle disequilibrium
nears the air/tissue interface. Beam modeling within the dose calculation algorithms must also employ an accurate method of
accounting tissue heterogeneity corrections in order to avoid dose overestimation or underestimation. Analytical anisotropic
algorithm (AAA) is one of the widely tested and validated dose calculation algorithms in external beam photon radiation ther-
apy. Recently, Acuros XB (AXB) was made available for photon dose calculations, and several studies have demonstrated better
dose prediction accuracy of the AXB over AAA. This article reviews the results from the treatment planning studies, which
have investigated the clinical dosimetric impact of the AXB and AAA on real lung cancer treatment plans.
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Introduction
Intensity modulated radiation therapy (IMRT) and volumet-
ric modulated arc therapy (VMAT) are two most commonly
used treatment delivery techniques in external beam photon
radiation therapy. Both the IMRT and VMAT are capable of
delivering conformal dose distributions to the target volume
while minimizing dose to the organs at risk (OAR).1 One of
the factors that could affect the accuracy of dose delivery in
external beam radiation therapy is the dose calculation algo-
rithm implemented within the treatment planning system
(TPS). The treatment delivery to various tumor sites such as
lung, breast, brain, oral cavity, and head and neck often in-
volves the tissue heterogeneities, which have different radio-
logic properties.2The Task Group 65 (TG-65) of the American
Association of Physicists in Medicine (AAPM) states that “the
general principle of 3% accuracy in dose delivery with the
corresponding need for better than 2% accuracy in correcting
for inhomogeneities is a reasonable, albeit challenging, goal.”2
A number of studies have shown the limitation of photon
dose calculation algorithms such as analytical anisotropic
algorithm (AAA), collapsed cone convolution (CCC) algo-
rithm, and pencil beam convolution (PBC) algorithm when
complex geometry with inhomogeneity is involved along the
photon beam path.3-12 Both the AAA and CCC are based on
the superposition/convolution method, which calculates the
dose by superposition of dose kernels of primary and scatter
components that are derived from the Monte Carlo (MC).
The tissue inhomogeneity correction in superposi-
tion/convolution method such as in the AAA is done both in
the beamlet direction and lateral directions.12-15 Specifically,
the beamlet direction includes the radiologic scaling of the
dose deposition functions, whereas the lateral directions in-
clude the electron-density-based scaling of photon scatter
kernels.12-15 The inhomogeneity correction in the PBC, how-
ever, is limited since it does not consider secondary electron
transport.3
Recently, Varian's Eclipse TPS (Varian Medical Systems, Palo
Alto, CA) has implemented Acuros XB (AXB) dose calcula-
tion algorithm, and it is commercially available for clinical
use. The AXB is considered to be similar to MC, and it utilizes
the linear Boltzmann transport equation (LBTE) and solves
numerically that describes the macroscopic behavior of ion-
izing particles as they travel through and interact with mat-
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ter.16 Detail descriptions on the AXB can be found else-
where.16-17
Current literature on the AXB shows that several investiga-
tors have validated the AXB by performing measurements
and Monte Carlo (MC) simulations16-23 and reported better
dose prediction accuracy using the AXB than using the AAA
in heterogeneous media. If the AXB is more accurate than the
AAA, it is imperative to evaluate the clinical dosimetric im-
pact of the AXB on real cancer treatment plans. The purpose
of this article is to review the current literature on the clini-
cal dosimetric evaluation of the AXB in lung cancer treat-
ment plans and summarize the latest findings on this topic.
The treatment planning for lung cancer is challenging, espe-
cially using stereotactic body radiation therapy (SBRT) tech-
nique, which involves low-density (air) medium and small
fields causing charge particle disequilibrium near the
air/tissue interface.24, 25 Moreover, both the calculated and
measured doses have strong dependence on the irradiated
inhomogeneous medium when electronic disequilibrium
occurs. 24 Therefore, beam modeling within the dose calcula-
tion algorithms must employ more accurate method of ac-
counting tissue heterogeneity corrections in order to avoid
dose overestimation or underestimation. However, due to the
difference in the beam modeling approach, computed results
of one dose calculation algorithm may not be in agreement
with that of another dose calculation algorithm.
Literature review
In one of the most recent studies on the AXB, Liu et al. 26
investigated the dosimetric impact of the AAA and AXB by
performing dose calculations on the treatment plans of 77
lung cancer patients. It was reported that the AXB resulted
lower conformation number (0.650 vs. 0.674) and higher
target dose heterogeneity (0.088 vs. 0.074) when compared to
the AAA. Similar result was reported in another study done
on 16 SBRT lung cases.22 Specifically, the AXB plans produced
lower plan conformity (0.77 vs. 0.82) and higher target dose
heterogeneity index (1.18 vs. 1.13) in comparison to the AAA
plans.22 Kathirvel et al. 20 also reported lower conformity in-
dex in the AXB plans (1.1) than in the AAA plans (1.2) for 5
SBRT cases. The evaluation of the maximum PTV dose
showed that the AXB plans produced smaller hot spot, with
an averaged maximum PTV dose in the AXB plans higher by
about 2.3% when compared to the AAA plans.22
Kroon et al. 19 evaluated the AXB for stage I and stage III lung
cancer patients. The findings from Kroon et al. 19 showed
lower near-minimum PTV dose in the AXB plans than in the
AAA plans, with differences of up to -12.3% for stage I (n =
8)and up to -0.8% for stage III (n = 7)lung cancer plans.19 The
mean PTV dose was also found to be lower in the AXB plans
by up to -4.9% than in the AAA plans.19 In agreement to their
findings 19, Rana et al. 22 reported that the AXB produced
lower mean and minimum PTV doses by -0.3% and -4.3%,
respectively, and Kathirvel et al. 20 showed lower mean PTV
dose in the AXB plans when compared to the one in the AAA
plans for 5 SBRT cases (102.2% vs. 102.9% of the prescription
dose) as well as for 5 non-SBRT cases (100.3% vs. 101.2% of
the prescription dose). However, the AXB plans may not al-
ways produce lower mean PTV dose, which may depend on
the photon beam energy and the location of the target. For
instance, Fogliata et al. 27 investigated the dosimetric impact
of energy comparing 6 and 15 MV photon beams, and their
results showed that, in comparison to the AAA, the AXB pre-
dicted lower mean PTV doses in the soft tissue by up to -1.7%
for 6 MV beam and up to -1.2% for 15 MV. However, for the
target in the lung, the mean PTV dose was higher by up to
1.2% for 6 MV beam and lower by up to 2.0% for 15 MV
beam.27 Hence, the variations in the PTV doses among dif-
ferent studies may be attributed to the difference in the PTV
volume, inclusion of lung/air volume inside the PTV, and
location of the PTV with respect to the lung and chest wall.
FIG. 1: A lung treatment plan setup using 2 partial arcs in Eclipse
TPS. This figure shows the isocenter at the center of the planning
target volume (PTV).
For the PTV, it is a standard practice to evaluate its coverage
by calculating a certain percentage (e.g., 95%) of the PTV
volume covered by the prescription dose or certain percent-
age of the prescription dose. For the same number of monitor
units (MUs), Rana et al. 22 reported that the PTV coverage in
the AXB plans was reduced by about 8% when compared to
the one in the AAA plans. Such reduction in the PTV cover-
age using the AXB raises the question if the prescription dose
needs to be adjusted for the AXB calculations in the lung
plans in order to improve the target coverage.  Based on the
results of Rana et al. 22, the MUs in the AXB plans had to be
increased by 0.4% to 5.3% in order to obtain the same PTV
coverage as in the AAA plans. Khan et al. 28 investigated the
effect of the AXB on MUs for 97 SBRT lung cases. The results
from Khan et al. 28 showed that the AXB required about 2%
higher MUs than the AAA in order to deliver the prescribed
dose.
Volume 2 • Number 1 • 2014 International Journal of Cancer Therapy and Oncology 3
www.ijcto.org
Copyright © Rana ISSN 2330-4049
From the clinical perspective of using the AXB, it raises the
question: can AXB meet the dosimetric criteria of currently
existing lung protocols? Recently, dosimetric evaluation of
both the AXB and AAA was done based on the RTOG 0813
dosimetric parameters for 14 SBRT cases.29 The results from
that study29 demonstrated that both the AXB and AAA could
meet the RTOG 0813 dosimetric criteria for the SBRT lung,
and the dosimetric values were lower in the AXB plans than
in the AAA plans except for the normal lung tissue. For the
lung, literature shows that the AXB produces slightly higher
relative volume of the normal lung tissue receiving 20 Gy
(V20) than the AAA.19, 20, 22, 29 Similarly, on average, higher
dosimetric values were obtained in the AXB plans for the
relative volume of normal lung receiving 5 Gy (V5).19, 22 In
contrast, the dosimetric values for both the spinal cord
(maximum dose) and heart (maximum and mean dose) were
found to be slightly lower in the AXB plans than in the AAA
plans.20, 22 However, there was no significant difference in the
mean dose to lung between the AXB and AAA plans.19, 20, 22
Discussion
Previous experimental and MC studies comparing AXB vs.
AAA have shown that the AXB is more accurate than the
AAA in the presence of inhomogeneity.16-23, 29-34 For instance,
in MC study involving low-density lung, Bush et al. 17 showed
the difference between the MC and AAA was higher (up to
17.5%) when compared to the one between the MC and AXB
(up to 4.5%). In a phantom study involving low-density me-
dium (lung insert and air gap), Rana et al. 29 showed that the
dose prediction error of the AAA could be up to 12.5% when
compared to the measurements, whereas the AXB had better
agreement with the measurements with a difference up to
2.8%.
Although the AXB could improve the accuracy of dose calcu-
lations and avoid miscalculation of the MUs in the lung can-
cer treatment plans, it is not clear which dose reporting mode
in AXB should be used for a clinical purpose. The AXB in the
Eclipse TPS can report the absorbed dose in two modes:
dose-to-medium (Dm) and dose-to-water (Dw). In recent
years, there has been significant interest in using dose calcu-
lation algorithms that are based on MC approach, which can
report the absorbed dose in Dm mode. For the AXB in the
Eclipse TPS, the default dose reporting mode is Dm. The major
difference between the AXB_Dm and AXB_Dw calculations
comes from the post-processing step. Specifically, the radia-
tion transport model in the AXB calculates the ener-
gy-dependent fluence, which gets multiplied by flux-to-dose
response functions, and this gives the absorbed dose in the
local voxel.16-17 Furthermore, for the AXB_Dm calculations,
the macroscopic energy deposition cross-section and atomic
density are based on the material properties of local voxel16-17;
whereas, energy deposition cross-sections for water are used
for the local media in the case of the AXB_Dw calcula-
tions.16-17
A number of studies have investigated the difference between
the Dm and Dw in AXB using MC simulations31 and phantom
measurements.32, 33, 34 While the MC simulations and phantom
measurements provide the dosimetric differences between
the AXB_Dm and AXB_Dw calculations31-34, the literature
comparing Dm vs. Dw on the real CT dataset of lung cancer
patients is yet to be published. However, it is relevant to
mention studies, which have investigated the dosimetric im-
pact of the Dm and Dw on the real cases other than lung can-
cer. Kan et al. 34 reported that, in comparison to the AXB_Dm,
the AXB_Dw will calculate higher mean PTV doses by up to
4% and higher mean doses to the tissues adjacent to bone by
up to about 2% for nasopharygeal carcinoma. Fogliata et al. 35
reported that the dose distributions calculated by the
AXB_Dw were about 5% higher than corresponding ones
calculated by the AXB_Dm for soft-tissue sarcoma patients.
Dogan et al. 36 reported that conversion of Dm to Dw in MC
method led dose discrepancies up to 8.0% for prostate cancer
and up to 5.8% for head and neck cancer. These discrepancies
between the Dm and Dw calculations may be due to the dif-
ference between stopping powers of water and materials of
different densities.
Since the Dw and Dm in the AXB can result different
dosimetric results, it is essential to further investigate if the
selection of either the Dm or Dw in AXB will make any signif-
icant difference for the lung plans in the clinical environ-
ment. Additionally, the dosimetric impact of the Dm and Dw
in the AXB may also depend on the treatment techniques
(e.g., IMRT, VMAT, and SBRT). The use of Dm vs. Dw for
external beam photon radiation therapy still remains a de-
bating topic.37 The supporters of the Dm reason that (1) con-
version from the Dm to Dw adds uncertainty in dose calcula-
tions due to uncertainties in computed stopping power ratios;
(2) Dm is more likely to provide a better measure of biological
response; (3) changing to the Dm will have minimal impact on
the treatment protocols; and (4) conversion of the Dm to Dw
defeats a potential advantage of using MC-based dose calcula-
tion algorithms. The supporters of the Dw argue that (1)
commissioning beam data are always measured in water; (2)
dosimetry calibration protocols are based in water; (3) clinical
experience in terms of tumor/tissue response is based on the
Dw, and (4) conversion from the CT numbers to media results
uncertainty in the medium type and composition.
Despite the ongoing debate on whether the Dw or Dm is the
most appropriate to report the dose in external beam photon
radiation therapy, the clinical outcome data comparing both
the Dm and Dw remains to be reported. Nevertheless, the cur-
rent literature supports the use of the AXB over the AAA for
dose calculations, especially for the lung treatment plans. It is
recommended that the AXB users consider the arguments37
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Dm vs. Dw before implementing either the AXB_Dm or
AXB_Dw for a routine clinical use.
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